What Proportion of Population has achieved Cellular Immunity against SARS-CoV-2 after Booster Vaccination: A Cross-sectional Study

Author:

Tani Yuta1,Takita Morihito1,Kobashi Yurie2,Wakui Masatoshi3,Zhao Tianchen2,Yamamoto Chika2,Saito Hiroaki2,Kawashima Moe2,Sugiura Sota1,Nishikawa Yoshitaka4,Omata Fumiya4,Shimazu Yuzo4,Kawamura Takeshi5,Sugiyama Akira5,Nakayama Aya5,Kaneko Yudai6,Kodama Tetsuhiko6,Kami Masahiro1,Tsubokura Masaharu2

Affiliation:

1. Medical Governance Research Institute

2. Department of Radiation Health Management, Fukushima Medical University, Fukushima

3. Department of Laboratory Medicine, Keio University School of Medicine

4. Department of General Internal Medicine, Hirata Central Hospital, Fukushima

5. Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo

6. Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo

Abstract

Abstract Background Booster vaccination reduces the incidence of severe cases and mortality of COVID-19, with cellular immunity playing an important role. However, little is known about what proportion of population has achieved cellular immunity after booster vaccination. Methods We conducted a Fukushima cohort database and assessed the humoral and cellular immunity in 2526 residents and HCWs in Fukushima Prefecture in Japan by continuous blood collection every 3 months since September 2021. We identified the proportion of people with induced cellular immunity after booster vaccination, using T-SPOT.COVID test, and analyzed their background characteristics. Results Among 1089 participants, 64.3 % (700/1089) had reactive cellular immunity after booster vaccination. Multivariable analysis revealed the following as independent predictors of reactive cellular immunity: age <40 years (adjusted odds ratio: 1.81, 95 % confidence interval: 1.19–2.75, p-value: 0.005), and adverse reactions after vaccination (1.92, 1.19-3.09, 0.007). Notably, despite IgG(S) and neutralizing antibody titers of ≥500 AU/mL, 33.9 % (349/1031) and 33.5 % (341/1017) of participants, respectively, did not have reactive cellular immunity. Conclusion This is the first study to evaluate cellular immunity at the population level after booster vaccination using T-SPOT.COVID test, however, with several limitations. Future studies will need to evaluate previously infected subjects and their T-cell subsets.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3